Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) Net Margin (2016 - 2026)

Champions Oncology has reported Net Margin over the past 17 years, most recently at 1.68% for Q1 2026.

  • For Q1 2026, Net Margin fell 2807.0% year-over-year to 1.68%; the TTM value through Jan 2026 reached 4.04%, down 1501.0%, while the annual FY2025 figure was 8.26%, 2276.0% up from the prior year.
  • Net Margin for Q1 2026 was 1.68% at Champions Oncology, down from 1.58% in the prior quarter.
  • Over five years, Net Margin peaked at 26.38% in Q1 2025 and troughed at 21.05% in Q1 2024.
  • A 5-year average of 4.42% and a median of 2.32% in 2022 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: surged 4743bps in 2025 and later plummeted -2807bps in 2026.
  • Year by year, Net Margin stood at 0.11% in 2022, then plummeted by -15872bps to 17.9% in 2023, then soared by 130bps to 5.4% in 2024, then tumbled by -71bps to 1.58% in 2025, then plummeted by -207bps to 1.68% in 2026.
  • Business Quant data shows Net Margin for CSBR at 1.68% in Q1 2026, 1.58% in Q4 2025, and 3.33% in Q3 2025.